Interleukin 6 Receptor
Inner-city kids with high IL-6 show more asthma symptoms, susceptibility to mouse allergen
Children who lived in inner cities and had high levels of IL-6 in their plasma appeared more likely to also have greater asthma symptoms, according to a study published in The Journal of Allergy and Clinical Immunology.
Better use of cytokine signalizing could ‘revolutionize’ rheumatology treatment
Correctly identifying cytokine pathways that are dysregulated in any given rheumatology patient could lead to better use of current biologic therapies, said a presenter at the 2022 Association of Women in Rheumatology annual conference.
JAK inhibitors as effective as TNF, IL-6 inhibitors for rheumatoid arthritis
Therapy discontinuance and 1-year response rates for Janus kinase and interleukin-6 inhibitors are similar to those of TNF inhibitors in patients with rheumatoid arthritis, according to data published in Annals of the Rheumatic Diseases.
Interleukin-6 blockade could reduce adverse events from immunotherapy
Interleukin-6 blockade appeared effective against immune-related adverse events among a small cohort of patients treated with immune checkpoint inhibitors for melanoma, according to study results published in Cancer Cell.
Olokizumab improves signs, symptoms, physical function in methotrexate-refractory RA
Olokizumab is associated with significant improvements in rheumatoid arthritis signs, symptoms and physical function in patients with inadequate response to methotrexate, according to data published in the Annals of the Rheumatic Diseases.
RESCUE
Ziltivekimab (Novo Nordisk) vs. placebo for reduction of inflammatory and thrombotic biomarker levels.
Ziltivekimab reduces inflammatory biomarkers tied to atherosclerosis
Ziltivekimab, a novel interleukin-6 ligand inhibitor, significantly reduced multiple inflammatory and thrombotic biomarkers associated with atherosclerosis, according to data presented at the American College Cardiology Scientific Session.
Moving away from ‘failed’ prednisone to IL-6 blockade in giant cell arteritis
Recent landmark study results have shown that interleukin-6 blockade may be superior to prolonged prednisone therapy in giant cell arteritis, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.